GeneLancet Biosciences Inc. today announced its selection as a performing member under the Advanced Research Projects Agency for Health (ARPA-H) Treating Hereditary Rare Diseases with In Vivo Precision Genetic Medicines (THRIVE) program.
Under this collaboration, GeneLancet will focus on identifying potent LgRNA constructs for inherited bone marrow failure (BMF) disorders and advancing them toward scale-up in collaboration with St. Jude Children’s Research Hospital and other partners.
Leave a Reply